Table 5

Thirty-day rate of postprocedure events among those who interrupted or did not interrupt therapy prior to the procedure

EventInterruptionNo interruptionOR [interruption vs no interruption] (95% CI)Interaction P†Adjusted OR [interruption vs no interruption] (95% CI)‡Interaction P†
Events/procedures (%) [n]*Events/procedures (%) [n]*
Stroke/systemic embolism       
 Overall 19/5741 (0.33) 23/3413 (0.67) 0.490 (0.267-0.901)  0.354 (0.168-0.747)  
 Apixaban 9/2877 (0.31) 7/1747 (0.40) 0.781 (0.290-2.103) .2352 0.651 (0.215-1.970) .3121 
 Warfarin 10/2864 (0.35) 16/1666 (0.96) 0.362 (0.164-0.799) 0.245 (0.090-0.668) 
Myocardial infarction       
 Overall 14/5741 (0.24) 16/3413 (0.47) 0.519 (0.253-1.066)  0.453 (0.212-0.972)  
 Apixaban 6/2877 (0.21) 6/1747 (0.34) 0.606 (0.195-1.883) .7213 0.549 (0.149-2.026) .7003 
 Warfarin 8/2864 (0.28) 10/1666 (0.60) 0.464 (0.182-1.180) 0.387 (0.152-0.985) 
Death       
 Overall 45/5741 (0.78) 58/3413 (1.70) 0.457 (0.309-0.676)  0.396 (0.260-0.603)  
 Apixaban 30/2877 (1.04) 24/1747 (1.37) 0.754 (0.440-1.295) .0078 0.671 (0.372-1.210) .0153 
 Warfarin 15/2864 (0.52) 34/1666 (2.04) 0.253 (0.137-0.466) 0.201 (0.104-0.387) 
Major bleeding       
 Overall 81/5566 (1.46) 79/3448 (2.29) 0.624 (0.458-0.850)  0.408 (0.288-0.578)  
 Apixaban 46/2792 (1.65) [2] 28/1768 (1.58) [6] 1.023 (0.639-1.636) .0041 0.787 (0.479-1.293) .0086 
 Warfarin 35/2774 (1.26) [0] 51/1680 (3.04) [11] 0.406 (0.264-0.625) 0.223 (0.133-0.374) 
Major/CRNM bleeding       
 Overall 133/5566 (2.39) 154/3448 (4.47) 0.517 (0.408-0.654)  0.384 (0.297-0.497)  
 Apixaban 72/2792 (2.58) [2] 61/1768 (3.45) [6] 0.736 (0.520-1.042) .0058 0.633 (0.440-0.910) .0118 
 Warfarin 61/2774 (2.20) [0] 93 / 1680 (5.54) [12] 0.373 (0.270-0.517) 0.235 (0.162-0.342) 
EventInterruptionNo interruptionOR [interruption vs no interruption] (95% CI)Interaction P†Adjusted OR [interruption vs no interruption] (95% CI)‡Interaction P†
Events/procedures (%) [n]*Events/procedures (%) [n]*
Stroke/systemic embolism       
 Overall 19/5741 (0.33) 23/3413 (0.67) 0.490 (0.267-0.901)  0.354 (0.168-0.747)  
 Apixaban 9/2877 (0.31) 7/1747 (0.40) 0.781 (0.290-2.103) .2352 0.651 (0.215-1.970) .3121 
 Warfarin 10/2864 (0.35) 16/1666 (0.96) 0.362 (0.164-0.799) 0.245 (0.090-0.668) 
Myocardial infarction       
 Overall 14/5741 (0.24) 16/3413 (0.47) 0.519 (0.253-1.066)  0.453 (0.212-0.972)  
 Apixaban 6/2877 (0.21) 6/1747 (0.34) 0.606 (0.195-1.883) .7213 0.549 (0.149-2.026) .7003 
 Warfarin 8/2864 (0.28) 10/1666 (0.60) 0.464 (0.182-1.180) 0.387 (0.152-0.985) 
Death       
 Overall 45/5741 (0.78) 58/3413 (1.70) 0.457 (0.309-0.676)  0.396 (0.260-0.603)  
 Apixaban 30/2877 (1.04) 24/1747 (1.37) 0.754 (0.440-1.295) .0078 0.671 (0.372-1.210) .0153 
 Warfarin 15/2864 (0.52) 34/1666 (2.04) 0.253 (0.137-0.466) 0.201 (0.104-0.387) 
Major bleeding       
 Overall 81/5566 (1.46) 79/3448 (2.29) 0.624 (0.458-0.850)  0.408 (0.288-0.578)  
 Apixaban 46/2792 (1.65) [2] 28/1768 (1.58) [6] 1.023 (0.639-1.636) .0041 0.787 (0.479-1.293) .0086 
 Warfarin 35/2774 (1.26) [0] 51/1680 (3.04) [11] 0.406 (0.264-0.625) 0.223 (0.133-0.374) 
Major/CRNM bleeding       
 Overall 133/5566 (2.39) 154/3448 (4.47) 0.517 (0.408-0.654)  0.384 (0.297-0.497)  
 Apixaban 72/2792 (2.58) [2] 61/1768 (3.45) [6] 0.736 (0.520-1.042) .0058 0.633 (0.440-0.910) .0118 
 Warfarin 61/2774 (2.20) [0] 93 / 1680 (5.54) [12] 0.373 (0.270-0.517) 0.235 (0.162-0.342) 
*

[n] represents number of bleedings followed by death within 30 days.

†

Interaction between interruption and treatment

‡

Adjusted for age, CHADS2 score, bridging, major/nonmajor procedure, and emergency/nonemergency procedure.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal